NCT05290883

Brief Summary

The project aims to investigate the antithrombotic activity of the novel yoghurt drink enriched with polar lipids derived from ovine milk. The health claims the formulated novel or functional food on EFSA guidelines "The scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health" and in a particular paragraph 5.4, "Claims on reduced platelet aggregation" "Platelet hyperactivity and hypercoagulability states are more commonly observed in subjects with cardiovascular (CV) risk factors. Healthy subjects or participants at very low risk of CV disease normally have non-activated circulating platelets. Reducing platelet aggregation in subjects with platelet activation during sustained exposure to the food/constituent (e.g., four weeks) would be a beneficial physiological effect". Within this investigation, the postprandial effects of this novel yoghurt drink against platelet aggregation are going to be studied ex vivo in blood from healthy human subjects as described in previously established procedures.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5

participants targeted

Target at below P25 for not_applicable cardiovascular-diseases

Timeline
Completed

Started May 2021

Shorter than P25 for not_applicable cardiovascular-diseases

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 14, 2021

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 18, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 25, 2021

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

March 4, 2022

Completed
18 days until next milestone

First Posted

Study publicly available on registry

March 22, 2022

Completed
Last Updated

November 7, 2022

Status Verified

November 1, 2022

Enrollment Period

2 months

First QC Date

March 4, 2022

Last Update Submit

November 2, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • An investigation of anti-platelet or antithrombotic effect of novel yoghurt drink by platelet aggregometry

    An investigation of anti-platelet or antithrombotic effect of novel yoghurt drink by platelet aggregometry will be carried out. The postprandial effect of novel yoghurt drink will be studied by using a platelet aggregation method as per literature. The antithrombotic effect of yoghurt drink lipids will be studied, using PAF and TRAP as platelet aggregation mediators. The investigation will be based on the study-specific platelet aggregometry analysis. Subjects will come to the lab after overnight fasting and they will be provided yoghurt drink (200mL); the activation of their platelets will be monitored over a period of 4 hours (0 to 4 hours study with 1 hour check points).

    0 mins (preprandially) to 240 mins (postprandially)

Study Arms (1)

Group A: Yoghurt drink (polar lipid) intervention

EXPERIMENTAL
Dietary Supplement: Novel yoghurt drink containing Polar Lipids

Interventions

Postprandial decreased platelet activation/aggregation in subjects, after the yoghurt drink consumption

Group A: Yoghurt drink (polar lipid) intervention

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy subjects need to have their dietary and dairy intake within the range \[1-2 serves per week\]

You may not qualify if:

  • Subjects will be excluded from the study if they are
  • Under medication and intake of dietary supplements
  • Treatment for blood clotting disorders or dyslipidaemia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Limerick

Limerick, V94 T9PX, Ireland

Location

Related Publications (1)

  • Tsoupras A, Zabetakis I, Lordan R. Platelet aggregometry assay for evaluating the effects of platelet agonists and antiplatelet compounds on platelet function in vitro. MethodsX. 2018 Dec 26;6:63-70. doi: 10.1016/j.mex.2018.12.012. eCollection 2019.

    PMID: 30619728BACKGROUND

Related Links

MeSH Terms

Conditions

Cardiovascular Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior Lecturer

Study Record Dates

First Submitted

March 4, 2022

First Posted

March 22, 2022

Study Start

May 14, 2021

Primary Completion

July 18, 2021

Study Completion

August 25, 2021

Last Updated

November 7, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will not share

Locations